Get the Stockscreener App
4.89
5.62%
0.26
Immuneering Corp stock is traded at $4.89, with a volume of 1.26M.
It is up +5.62% in the last 24 hours and up +15.88% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$4.63
Open:
$4.68
24h Volume:
1.26M
Relative Volume:
1.05
Market Cap:
$177.60M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-2.5873
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+30.05%
1M Performance:
+15.88%
6M Performance:
+177.84%
1Y Performance:
+365.71%
1-Day Range:
$4.5022
$4.98
1-Week Range:
$3.25
$4.98
52-Week Range:
$1.01
$4.98
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.89 | 127.12M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Volatility clustering patterns for Immuneering CorporationWeekly Trade Summary & AI Enhanced Trading Signals - Newser
Should you hold or exit Immuneering Corporation nowJuly 2025 Momentum & Low Risk Investment Opportunities - Newser
Understanding Immuneering Corporation’s price movementJuly 2025 EndofMonth & Reliable Volume Spike Trade Alerts - Newser
Mizuho Securities Maintains Buy Rating on Immuneering with $10 Price Target - AInvest
Live market analysis of Immuneering CorporationJuly 2025 Fed Impact & Free Community Supported Trade Ideas - Newser
Immuneering Corporation stock prediction for this week2025 Year in Review & Proven Capital Preservation Tips - Newser
Pattern recognition hints at Immuneering Corporation upsideEarnings Overview Summary & Fast Exit and Entry Trade Guides - Newser
Published on: 2025-08-19 23:23:02 - Newser
What machine learning models say about Immuneering CorporationJuly 2025 Momentum & Verified Momentum Watchlists - Newser
Immuneering Corporation stock trendline breakdown2025 Dividend Review & Community Shared Stock Ideas - Newser
Leading vs lagging indicators on Immuneering Corporation performanceWeekly Trading Summary & Free Weekly Watchlist of Top Performers - Newser
Does Immuneering Corporation show high probability of reboundTrade Analysis Report & Proven Capital Preservation Methods - Newser
Immuneering Corporation’s volatility index tracking explainedInflation Watch & Real-Time Chart Pattern Alerts - Newser
Published on: 2025-08-18 00:12:21 - Newser
Is this a good reentry point in Immuneering Corporation2025 Short Interest & Verified Short-Term Trading Plans - Newser
Order flow analysis tools used on Immuneering Corporation2025 Market Sentiment & Free Technical Confirmation Trade Alerts - Newser
Immuneering’s (IMRX) “Buy” Rating Reiterated at Chardan Capital - Defense World
Using Python tools to backtest Immuneering Corporation strategiesIndex Update & Low Risk High Reward Ideas - Newser
Can Immuneering Corporation maintain its current growth rateJuly 2025 PostEarnings & Free Weekly Watchlist of Top Performers - sundaytimes.kr
Applying chart zones and confluence areas to Immuneering CorporationWeekly Profit Summary & Fast Moving Stock Watchlists - Newser
Immuneering's 22% Surge: A Technical Rebound or Sector Catalyst? - AInvest
IMRX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Immuneering Corp Q2 2025 Earnings: EPS Beats Estimate, Reports $14.4M Net Loss, Highlights Robust Cash Position and Clinical Advancements - AInvest
Immuneering Corp. Reports Strong Trial Results and Patent Win - TipRanks
Immuneering Reports Q2 GAAP EPS of -$0.40, Cash Reserves at $26.4 Million. - AInvest
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Price Target at $13.25 - Defense World
Can swing trading help recover from Immuneering Corporation lossesRisk-Managed Swing Setup and Signal Analysis - Newser
Is Immuneering Corporation showing signs of accumulationFree Trend Analysis for Safer Trades - Newser
Is Immuneering Corporation stock entering bullish territoryGold Moves & Safe Capital Investment Plans - Newser
Quant Tools Rank Immuneering Corporation as High Risk High RewardStep-by-Step Trade Signal Implementation Guide Ready - metal.it
Is it the right time to buy Immuneering Corporation stockExtraordinary earning power - Jammu Links News
What drives Immuneering Corporation stock priceGet high-impact stock recommendations now - Jammu Links News
How many analysts rate Immuneering Corporation as a “Buy”Build a diversified portfolio for maximum returns - Jammu Links News
What are Immuneering Corporation company’s key revenue driversExceptional stock performance - Jammu Links News
Multi asset correlation models including Immuneering CorporationFree Multi-Bagger Potential Stock Forecast Tools - Newser
How does Immuneering Corporation compare to its industry peersStock Strategy Entry Points Backed By Experts - Jammu Links News
Real time breakdown of Immuneering Corporation stock performanceStrong Buy Opportunity with Volume Support - Newser
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
How Efficient Is Immuneering Corporation at Controlling Operating CostsFree Trade Timing Strategy With Technical Data - Newser
Immuneering Corporation’s Price Action Aligns with Quant SignalsConsistent Income Focused Trade List Analyzed - metal.it
Published on: 2025-07-28 06:27:12 - Jammu Links News
What makes Immuneering Corporation stock price move sharplyProven High Yield Signals - metal.it
How strong is Immuneering Corporation company’s balance sheetBreakout profit opportunities - Jammu Links News
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immuneering Corp Stock (IMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| HAUSMAN DIANA | Director |
Jul 02 '25 |
Buy |
3.60 |
2,500 |
8,989 |
2,500 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jul 02 '25 |
Buy |
3.57 |
700 |
2,499 |
10,729 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jul 02 '25 |
Buy |
3.53 |
7,015 |
24,792 |
2,312,852 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jul 01 '25 |
Buy |
3.38 |
2,985 |
10,087 |
2,305,837 |
| Schall Thomas J. | Director |
Jun 27 '25 |
Buy |
3.66 |
9,500 |
34,788 |
52,885 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 20 '25 |
Buy |
2.70 |
7,415 |
20,020 |
353,311 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 23 '25 |
Buy |
2.43 |
6,007 |
14,596 |
359,318 |
| Brakewood Harold Eugene | Chief Business Officer |
Jun 20 '25 |
Buy |
2.53 |
1,900 |
4,804 |
5,800 |
| Feinberg Peter | Director |
Jun 18 '25 |
Buy |
2.53 |
25,000 |
63,188 |
136,766 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jun 18 '25 |
Buy |
2.39 |
21,000 |
50,144 |
2,302,852 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):